Akcea Therapeutics, Inc. announced that the company has promoted Kyle Jenne to chief commercial officer. This promotion is part of Akcea’s strategy to expand its operations as they continue to further invest in the TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) launches globally, add new antisense assets to their pipeline and support the potential in-licensing of additional investigational therapies to address rare and serious unmet medical needs.